Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067016 | 1.00 | LMNA (0.44) | LMNAMAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1067014 | 1.00 | LMNA (0.44) | LMNAMAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1066360 | 0.89 | MAPT (0.47) | LMNAMAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1066356 | 0.89 | MAPT (0.47) | LMNAMAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1066358 | 0.89 | MAPT (0.47) | LMNAMAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1065611 | 0.86 | TDP1 (0.46) | LMNAMAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1065614 | 0.86 | TDP1 (0.46) | LMNAMAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1065610 | 0.86 | TDP1 (0.46) | LMNAMAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL1067468 | 0.86 | L3MBTL1 (0.42) | LMNAMAPTL3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL1067465 | 0.86 | L3MBTL1 (0.42) | LMNAMAPTL3MBTL1ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206175-B1 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | HUA MEDICINE SHANGHAI LTD (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-20240217913-A2 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20230312455-A1 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312455-A1 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| CN-114085146-B | Preparation of substituted acrylate compounds | 华领医药技术（上海）有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4206175-A1 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | Hua Medicine (Shanghai) Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| CN-114085146-A | Preparation of substituted acrylate compounds | 华领医药技术（上海）有限公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312455-A1 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | ACR, ADCYAP1R1, GNPAT | LMNA 923/4885MAPT 3852/4885L3MBTL1 4773/4885 |
| US-20240217913-A2 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | ACR, ADCYAP1R1, GNPAT | LMNA 923/4885MAPT 3852/4885L3MBTL1 4773/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | LMNA 3936/4885MAPT 4151/4885L3MBTL1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.